GlassScriptPhysician profile
Jason B Goolsby
NPI 1801925938
$37,077.26
in general payments reported to CMS, 2019-2025
40 companies · $4,027 in 2025
The $4,027 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,356 · 2020: $973 · 2021: $12K · 2022: $6,400 · 2023: $4,498 · 2024: $3,321 · 2025: $4,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,514 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,113 · Consulting Fee: $1,288 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $850 · Education: $41.52 · Travel and Lodging: $39.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,514.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,112.50 |
| Consulting Fee | $1,288.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $850.00 |
| Education | $41.52 |
| Travel and Lodging | $39.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,032.91 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $5,871.57 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,534.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Biogen, INC. | $1,436.47 | 2023-2025 | Skyclarys, Skyclarys |
| Novo Nordisk INC | $1,288.41 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,215.99 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Axsome Therapeutics, INC. | $941.05 | 2024-2025 | Auvelity, Symbravo |
| Glaxosmithkline, LLC. | $864.87 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $803.67 | 2020-2025 | Trintellix |
| Allergan, INC. | $792.04 | 2019-2021 | |
| Lilly USA, LLC | $757.82 | 2020-2025 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $717.64 | 2019-2025 | |
| Amgen INC. | $612.13 | 2020-2025 | Otezla, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $482.20 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $450.33 | 2021-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Goolsby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.